Cathy Eng, MD, FACP, medical oncologist, The University of Texas MD Anderson Cancer Center, discusses the combination of bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as a treatment for patients with metastatic colorectal cancer (mCRC).
Cathy Eng, MD, FACP, medical oncologist, The University of Texas MD Anderson Cancer Center, discusses the combination of bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as a treatment for patients with metastatic colorectal cancer (mCRC). Eng says the combination came about through medical professional's use of bevacizumab in the frontline as a treatment for mCRC, leading one Italian research group to start the TRIBE trial.
The trial studied bevacizumab plus FOLFOXIRI and found the combination improved both progression-free survival (PFS) and response rates over FOLFIRI (irinotecan, fluorouracil, and folinate) alone. The combination also found that patients receiving the combination had a 5-year overall survival (OS) of 25%, as opposed to the standard 13% in mCRC patients. Eng says the one downside to the combination is that patients become more prone to myelosuppression.
Early Data Shows Axi-Cel’s Potential in Treating R/R Primary and Secondary CNS Lymphomas
June 13th 2024Findings from a phase 1 trial presented at ASCO showed that axicabtagene ciloleucel was safe with clinical activity seen among patients with relapsed/refractory primary and secondary central nervous system lymphoma.
Read More
High CR Rate in BCG-Unresponsive NMIBC With Cretostimogene Grenadenorepvec/Pembro
June 5th 2024A high complete response rate was achieved in patients with BCG–unresponsive NMIBC using the combination of cretostimogene grenadenorepvec and pembrolizumab, according to final phase 2 CORE-001 trial results.
Read More